Understanding Benzo Reversal: The Role of Flumazenil in Benzodiazepine Overdose and Sedation

Flumazenil stands as a crucial benzodiazepine antagonist, primarily deployed in emergency scenarios involving benzodiazepine overdose. Its FDA-approved applications prominently feature its role as a reversal agent for benzodiazepine overdose and in counteracting postoperative sedation induced by benzodiazepine anesthetics. Specifically, flumazenil injection is indicated for the complete or partial reversal of benzodiazepine sedative effects during conscious sedation and general anesthesia across both adult and pediatric patient groups. This activity will delve into the indications, mechanism of action, dosing guidelines, potential adverse effects, contraindications, monitoring protocols, and toxicity profiles of flumazenil. The aim is to equip clinicians with the essential knowledge to effectively guide patient therapy, ensuring optimal outcomes in Benzo Reversal. Empowering healthcare providers with comprehensive insights into flumazenil therapy is of utmost importance for patient safety and effective treatment strategies.

This educational activity is structured to enhance the capabilities of healthcare professionals by clarifying their roles and promoting seamless interdisciplinary collaboration. A robust understanding of flumazenil’s pharmacology enables prescribing clinicians to customize treatment strategies to meet the unique needs of each patient. This personalized approach ensures the safe and effective benzo reversal of benzodiazepine-induced sedation. Such a holistic strategy is vital for minimizing the risks of adverse reactions and elevating the standards of care in benzodiazepine overdose management.

Objectives:

• Recognize patient scenarios that necessitate flumazenil administration for benzo reversal in benzodiazepine overdose.
• Distinguish between the FDA-approved and off-label applications of flumazenil as an antidote.
• Assess patients for potential withdrawal symptoms and adverse reactions following flumazenil administration.
• Foster effective collaboration within interprofessional healthcare teams to optimize treatment outcomes for patients benefiting from flumazenil in benzo reversal.

Access free multiple choice questions on this topic.

Indications for Flumazenil in Benzo Reversal

Flumazenil is recognized as a potent benzodiazepine antagonist, playing a vital role in reversing the effects of these sedative medications.[1], [2]

FDA-Approved Indications

• Benzodiazepine Overdose Treatment: Flumazenil is a cornerstone in the treatment of benzodiazepine overdose in both adult (Category B, Class IIa) and pediatric (Category C, Class IIb) populations. Its effectiveness in benzo reversal during overdose situations is well-established.

• Postoperative Sedation Reversal from Benzodiazepine Anesthetics: It is also FDA-approved for the reversal of postoperative sedation resulting from benzodiazepine anesthetics in adults (Category B, Class IIa) and children (Category B, Class IIa). This application in benzo reversal aids in faster recovery after surgical procedures.

  Flumazenil is specifically indicated for achieving complete or partial benzo reversal of the sedative effects of benzodiazepines in both conscious sedation and general anesthesia for adult and pediatric patients. Furthermore, flumazenil accelerates recovery from sedation following minor surgical interventions and reduces the duration of post-operative monitoring, facilitating earlier patient discharge after minor surgeries.

  In adults, flumazenil is crucial for managing and treating benzodiazepine overdose, particularly in reversing coma induced by benzodiazepine overdose. Flumazenil exhibits greater efficacy in reversing sedation or coma in cases of benzodiazepine intoxication compared to situations involving multiple drug overdoses.

Off-Label Uses

Beyond its FDA-approved uses, flumazenil has demonstrated potential in several off-label applications, including:

• Alcohol withdrawal syndrome
• Baclofen reversal
• Idiopathic recurring stupor
• Cannabis toxicity
• Hepatic encephalopathy
• Benzodiazepine detoxification

While these uses are not officially approved, they highlight the broader potential of flumazenil in managing various conditions, particularly those involving central nervous system depression or paradoxical reactions.

Mechanism of Action of Flumazenil in Benzo Reversal

Flumazenil’s effectiveness as a benzo reversal agent lies in its mechanism of action as a benzodiazepine antagonist. It functions by competitively inhibiting the activity of benzodiazepines and non-benzodiazepine substances that interact with the benzodiazepine receptor site on the GABA/benzodiazepine receptor complex. Essentially, it can reverse the binding of benzodiazepines to these receptors.[12] When administered intravenously (IV), flumazenil antagonizes the sedative effects, memory impairment, and psychomotor deficits induced by benzodiazepines.[13] This competitive antagonism is the core of its ability to achieve benzo reversal.

Pharmacokinetics

Understanding flumazenil’s pharmacokinetic properties is crucial for effective benzo reversal.

• Absorption: Following parenteral administration, flumazenil acts rapidly, with an onset of action in approximately 1 to 2 minutes. A significant 80% of the therapeutic response is typically observed within the first 3 minutes. The peak effect is reached within 6 to 10 minutes post-administration. The duration of flumazenil’s effects ranges from 19 to 50 minutes, influenced by the dose administered and the plasma concentrations of the benzodiazepines being antagonized.

• Distribution: Flumazenil distributes extensively throughout the extracellular space. The initial apparent volume of distribution is 0.5 L/kg, and the steady-state plasma concentration ranges from 0.9 to 1.1 L/kg. Plasma protein binding is approximately 50%, with albumin contributing to about two-thirds of this binding.

• Metabolism: Flumazenil undergoes near-complete metabolism, with only minor fractions ([14]

• Elimination: Radiolabeled flumazenil is eliminated within 72 hours, with 90% to 95% of radioactivity excreted in urine and 5% to 10% in feces. Hepatic metabolism is the primary route of clearance. Studies in healthy volunteers show total clearance rates ranging from 0.8 to 1.0 L/hr/kg. The elimination half-life is approximately 54 minutes, with a variability of 21% (ranging from 41 to 79 minutes). This relatively short half-life means that re-sedation can occur within 1 to 2 hours after administration, potentially necessitating repeat doses for sustained benzo reversal.[15]

Administration of Flumazenil for Benzo Reversal

Effective administration is key to successful benzo reversal using flumazenil.

Available Dosage Forms and Strengths

Flumazenil is formulated for IV infusion. The injectable solution contains a concentration of 0.1 mg/mL of flumazenil. Once drawn into a syringe or mixed with D5W, LR, or NS, the solution remains stable for 24 hours. Administration is typically via free-flowing IV infusion into a large vein or through a series of small, carefully timed injections.[16]

Adult Dosage

• FDA Dosage for Benzodiazepine Overdose Management:

  • Initial dose: 0.2 mg IV administered over 30 seconds.
  • If the desired level of consciousness is not achieved after 30 seconds, administer an additional 0.3 mg IV over 30 seconds.
  • Repeat doses of 0.5 mg IV over 30 seconds at 1-minute intervals, up to a maximum cumulative dose of 3 mg, may be given.
  • Patients showing only partial response to 3 mg may require further slow titration to a total dosage of 5 mg. If no response is observed after 5 mg, benzodiazepine is likely not the primary cause of sedation, and further flumazenil administration is unlikely to be effective.
  • In cases of recurrent sedation, repeat doses can be administered at 20-minute intervals, not exceeding 1 mg (0.5 mg/minute) per dose or 3 mg/hour.

• FDA Dosage for Benzodiazepine Reversal in Conscious Sedation or General Anesthesia:

  • Initial dose: 0.2 mg IV over 15 seconds.
  • If the desired level of consciousness is not achieved after 45 seconds, repeat 0.2 mg IV at 1-minute intervals. Up to 4 additional doses may be needed.
  • Maximum total cumulative dose: 1 mg.
  • For recurrent sedation, repeat doses may be given at 20-minute intervals, not exceeding 0.2 mg/minute per dose or 3 mg/hour total.

It is important to note that the American Association for the Study of Liver Diseases indicates that flumazenil provides only transient improvement in overt hepatic encephalopathy without long-term survival benefits.[17]

Specific Patient Populations

• Hepatic Impairment: Dosage adjustments are necessary for patients with hepatic insufficiency. While the initial dose for benzo reversal remains the same, subsequent doses should be reduced in dosage or frequency due to altered metabolism.[18]

• Renal Impairment: FDA-approved labeling specifies no dosage adjustments are typically required for renal impairment (creatinine clearance

• Pregnancy Considerations: Research on poisoning cases in pregnant individuals shows flumazenil as a frequently used antidote. In benzodiazepine toxicity during pregnancy, while supportive measures are often effective, case reports highlight flumazenil’s potential to reverse fetal cardiac rhythm abnormalities caused by maternal diazepam overdose.[19]

• Breastfeeding Considerations: Caution is advised when administering flumazenil to breastfeeding women, as its presence in human milk is not fully understood. Limited data exists on flumazenil use during breastfeeding. If necessary for the mother, breastfeeding can continue, but abstaining for 4 to 5 hours post-administration, considering the drug’s 54-minute half-life, can minimize infant exposure.[20]

• Pediatric Patients: FDA-approved for benzo reversal in conscious sedation or general anesthesia.

  • Initial dose: 0.01 mg/kg administered over 15 seconds (up to a maximum of 0.2 mg).
  • If desired consciousness level is not reached after 45 seconds, repeat 0.01 mg/kg (up to 0.2 mg) at 1-minute intervals, up to 4 additional doses.
  • Maximum total cumulative dose: 1 mg or 0.05 mg/kg, whichever is lower.
  • Clinical trials reported a mean total dose of 0.65 mg (range: 0.08 to 1 mg).

• Older Patients: Studies indicate that while benzodiazepine doses for sedation induction should be reduced in older adults, the standard flumazenil dosage is effective for benzo reversal in this population, even in individuals over 80 years old.

Adverse Effects of Flumazenil in Benzo Reversal

While flumazenil is effective in benzo reversal, it is associated with potential adverse effects.

Serious Adverse Events

• Sedation recurrence
• Neurologic effects, including seizures
• Arrhythmias[21]

Common Adverse Events

• Cardiovascular: Bradycardia, tachycardia, hypertension, chest pain
• Neurologic: Confusion, dizziness, headache, impaired cognition, opisthotonus, shivering, somnolence
• Gastrointestinal: Nausea, vomiting
• Immunologic: Injection site reaction
• Ophthalmic: Visual field defects, diplopia, blurred vision
• Otic: Transient hearing impairment
• Dermatologic: Diaphoresis, injection site pain
• Psychiatric: Anxiety, psychotic disorder, agitation, panic attack[22]

Drug-Drug Interactions

• Tricyclic antidepressants: Caution is advised when using flumazenil in mixed drug overdoses, particularly those involving tricyclic antidepressants like amitriptyline, nortriptyline, clomipramine, and imipramine, due to an increased risk of seizures. In severe cyclic antidepressant toxicity characterized by dysrhythmia, anticholinergic signs, and cardiovascular collapse, flumazenil should be avoided. Supportive care should be prioritized until antidepressant toxicity symptoms resolve.[23]

• Vecuronium: Vials of flumazenil and vecuronium may appear similar after removing their colored caps. Storing both in procedural areas increases the risk of medication mix-ups.[24]

Contraindications and Warnings for Benzo Reversal with Flumazenil

Understanding contraindications and warnings is crucial for the safe use of flumazenil in benzo reversal.

Contraindications

• Hypersensitivity to flumazenil or benzodiazepines.
• Benzodiazepine use for managing life-threatening conditions like increased intracranial pressure or status epilepticus.

Warnings and Precautions

• Flumazenil can trigger panic attacks in patients with a history of panic disorder.
• Convulsions may occur in patients with chronic benzodiazepine dependence.
• Flumazenil may precipitate seizures or altered cerebral blood flow in patients with head injuries.
• Increased seizure risk exists in epileptic patients on long-term benzodiazepine therapy.
• Caution is advised in patients with drug dependency or alcoholism due to a higher incidence of benzodiazepine tolerance and dependence.
• Flumazenil should not be the primary treatment for patients with severe lung disease experiencing respiratory depression secondary to benzodiazepines.
• Signs of tricyclic antidepressant overdose or mixed overdoses are contraindications for flumazenil use.[US Box Warning]

Monitoring Patients Post-Benzo Reversal with Flumazenil

Post-administration monitoring is essential after benzo reversal with flumazenil.

Patients should be monitored for respiratory depression, benzodiazepine withdrawal symptoms, and other residual benzodiazepine effects for at least 2 hours.[31] Seizures can occur as a consequence of flumazenil administration. Seizures induced by flumazenil may require treatment with larger doses of benzodiazepines.[27] Patients should be monitored for the potential return of sedation, particularly in those with benzodiazepine tolerance or in cases of long-acting benzodiazepine overdose. Re-sedation can be managed in adults by administering flumazenil again until the desired therapeutic effect is achieved.[32]

Toxicity of Flumazenil in Benzo Reversal

While flumazenil overdose is rare, it’s important to understand its toxicity profile in the context of benzo reversal.

Flumazenil has been linked to the precipitation of seizures in benzodiazepine-dependent patients, especially those with a history of seizures. However, flumazenil overdose itself is extremely uncommon.

Clinical Features of Flumazenil Toxicity

• Anxiety
• Agitation
• Increased muscle tone
• Hyperesthesia
• Seizures

Management of Flumazenil Toxicity

• There is no specific antidote for flumazenil toxicity.
• Management of mild to severe toxicity focuses on symptomatic and supportive care.

Consult Criteria

• Consultation with a medical toxicologist or local poison center is recommended for any patient exhibiting suspected severe adverse effects following flumazenil administration, such as seizures, dysrhythmias, and hypotension.

Enhancing Healthcare Team Outcomes in Benzo Reversal

In the context of the ongoing drug overdose epidemic, it is crucial for nurses, pharmacists, and clinicians to be proficient in using flumazenil for benzo reversal. This competitive benzodiazepine antagonist can rapidly reverse benzodiazepine overdose. Despite initial enthusiasm, many experts now advocate for cautious use, recognizing that the risks may sometimes outweigh the benefits. A key concern is the potential for flumazenil to precipitate seizures and withdrawal in patients who are benzodiazepine-dependent for medical reasons. It is critical that all clinicians are aware of the contraindications, particularly in patients with a history of seizures, head injury, or tricyclic antidepressant ingestion. Flumazenil is most ideally suited for situations where a benzodiazepine-naive individual has overdosed. Nurses and pharmacists play a vital role in patient education regarding benzodiazepine use, emphasizing the risks of addiction and physical dependence.[36], [37]

Generally, isolated benzodiazepine overdoses rarely result in significant mortality. The risk escalates when benzodiazepines are co-ingested with alcohol or other illicit substances. In most cases of isolated benzodiazepine overdose, supportive management is often sufficient. However, some patients may develop complications such as rhabdomyolysis and aspiration pneumonia. Overall, the use of flumazenil for managing benzodiazepine overdose is becoming more selective, as its potential to cause harm in certain patient populations is increasingly recognized.[1], [38]

Emergency department clinicians typically manage flumazenil administration in overdose situations. Hospital pharmacists are essential for ensuring accurate flumazenil dosing. Critical care consultation is necessary in severe poisoning cases involving respiratory depression. Furthermore, medical toxicologist consultation is frequently required for patients with multiple-drug ingestions. Effective interprofessional collaboration among clinicians (MDs, DOs, NPs, and PAs) is paramount for optimizing patient outcomes in benzo reversal. An interprofessional team approach is crucial for maximizing efficacy and minimizing the potential risks associated with flumazenil therapy in benzo reversal.

Review Questions

(Note: Review Questions are present in the original article but not included here as per instructions)

References

1.Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD011481. [PMC free article: PMC6513394] [PubMed: 29543325]

2.Zhu S, Noviello CM, Teng J, Walsh RM, Kim JJ, Hibbs RE. Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. [PMC free article: PMC6220708] [PubMed: 29950725]

3.Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018: A Report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. Anesthesiology. 2018 Mar;128(3):437-479. [PubMed: 29334501]

4.Seelhammer TG, DeGraff EM, Behrens TJ, Robinson JC, Selleck KL, Schroeder DR, Sprung J, Weingarten TN. [The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes]. Braz J Anesthesiol. 2018 Jul-Aug;68(4):329-335. [PMC free article: PMC9391726] [PubMed: 29631877]

5.Wu Q, Xu F, Wang J, Jiang M. Comparison of Remimazolam-Flumazenil versus Propofol for Recovery from General Anesthesia: A Systematic Review and Meta-Analysis. J Clin Med. 2023 Nov 26;12(23) [PMC free article: PMC10707179] [PubMed: 38068368]

6.Nelson LS. Alcohol withdrawal and flumazenil: not for the faint of heart. J Med Toxicol. 2014 Jun;10(2):123-5. [PMC free article: PMC4057543] [PubMed: 24595919]

7.Franchitto N, Pelissier F, Lauque D, Simon N, Lançon C. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol. 2014 Jan-Feb;49(1):79-83. [PubMed: 24226812]

8.Asthana V, Agrawal S, Goel D, Sharma JP. Idiopathic recurrent stupor mimicking status epilepticus. Singapore Med J. 2008 Oct;49(10):e276-7. [PubMed: 18946597]

9.Crippa JA, Derenusson GN, Chagas MH, Atakan Z, Martín-Santos R, Zuardi AW, Hallak JE. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J. 2012 Jan 25;9:7. [PMC free article: PMC3294246] [PubMed: 22273390]

10.Reinert JP, Burnham K. Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review. J Pharm Pract. 2021 Dec;34(6):922-933. [PubMed: 32878558]

11.Benini A, Gottardo R, Chiamulera C, Bertoldi A, Zamboni L, Lugoboni F. Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification. Front Psychiatry. 2021;12:646038. [PMC free article: PMC8012511] [PubMed: 33815177]

12.An H, Godwin J. Flumazenil in benzodiazepine overdose. CMAJ. 2016 Dec 06;188(17-18):E537. [PMC free article: PMC5135539] [PubMed: 27920113]

13.Amrein R, Hetzel W, Hartmann D, Lorscheid T. Clinical pharmacology of flumazenil. Eur J Anaesthesiol Suppl. 1988;2:65-80. [PubMed: 2842143]

14.van Rij CM, Huitema AD, Swart EL, Greuter HN, Lammertsma AA, van Loenen AC, Franssen EJ. Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. Br J Clin Pharmacol. 2005 Nov;60(5):477-85. [PMC free article: PMC1884950] [PubMed: 16236037]

15.Kiyama S. Re-sedation after a large dose of flumazenil. J Anesth. 2023 Feb;37(1):161. [PubMed: 36242628]

16.Parthvi R, Mehra S. Flumazenil for Mixed Drug Overdose. Am J Ther. 2018 Nov/Dec;25(6):e676-e677. [PubMed: 28708699]

17.Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35. [PubMed: 25042402]

18.Janssen U, Walker S, Maier K, von Gaisberg U, Klotz U. Flumazenil disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1989 Sep;46(3):317-23. [PubMed: 2505960]

19.Zelner I, Matlow J, Hutson JR, Wax P, Koren G, Brent J, Finkelstein Y., Toxicology Investigators Consortium (ToxIC). Acute Poisoning During Pregnancy: Observations from the Toxicology Investigators Consortium. J Med Toxicol. 2015 Sep;11(3):301-8. [PMC free article: PMC4547956] [PubMed: 25783189]

20.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Aug 15, 2023. Flumazenil. [PubMed: 37603673]

21.Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication–A Systematic Review with Meta-Analyses of Randomised Trials. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):37-44. [PubMed: 26096314]

22.Wong M. Reversal Agents in Sedation and Anesthesia Practice for Dentistry. Anesth Prog. 2022 Apr 01;69(1):49-58. [PMC free article: PMC8985463] [PubMed: 35377935]

23.Veiraiah A, Dyas J, Cooper G, Routledge PA, Thompson JP. Flumazenil use in benzodiazepine overdose in the UK: a retrospective survey of NPIS data. Emerg Med J. 2012 Jul;29(7):565-9. [PubMed: 21785147]

24.Grissinger M. Paralyzed by Mistakes – Reassess the Safety of Neuromuscular Blockers in Your Facility. P T. 2019 Mar;44(3):91-107. [PMC free article: PMC6385733] [PubMed: 30828226]

25.Woolf AD, Erdman AR, Nelson LS, Caravati EM, Cobaugh DJ, Booze LL, Wax PM, Manoguerra AS, Scharman EJ, Olson KR, Chyka PA, Christianson G, Troutman WG. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(3):203-33. [PubMed: 17453872]

26.Seger DL. Flumazenil–treatment or toxin. J Toxicol Clin Toxicol. 2004;42(2):209-16. [PubMed: 15214628]

27.Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother. 1994 Dec;28(12):1347-9. [PubMed: 7696723]

28.Sivilotti ML. Flumazenil, naloxone and the ‘coma cocktail’. Br J Clin Pharmacol. 2016 Mar;81(3):428-36. [PMC free article: PMC4767210] [PubMed: 26469689]

29.Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, Hoyte CO, Mazer-Amirshahi ME, Stolbach A, St-Onge M, Thompson TM, Wang GS, Hoover AV, Drennan IR., American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023 Oct 17;148(16):e149-e184. [PubMed: 37721023]

30.Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther. 1992 Mar-Apr;14(2):292-305. [PubMed: 1611650]

31.Rousseau-Blass F, Cribb AE, Beaudry F, Pang DS. A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). J Am Assoc Lab Anim Sci. 2021 May 01;60(3):319-328. [PMC free article: PMC8145127] [PubMed: 33673881]

32.Maxa JL, Ogu CC, Adeeko MA, Swaner TG. Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity. Pharmacotherapy. 2003 Nov;23(11):1513-6. [PubMed: 14620397]

33.Wallace IR, Campbell EC, Trimble M. Use of a flumazenil infusion to treat chlordiazepoxide toxicity. Acute Med. 2017;16(1):30-34. [PubMed: 28424803]

34.Vukcević NP, Ercegović GV, Segrt Z, Djordjević S, Stosić JJ. Benzodiazepine poisoning in elderly. Vojnosanit Pregl. 2016 Mar;73(3):234-8. [PubMed: 27295906]

35.Kreshak AA, Cantrell FL, Clark RF, Tomaszewski CA. A poison center’s ten-year experience with flumazenil administration to acutely poisoned adults. J Emerg Med. 2012 Oct;43(4):677-82. [PubMed: 22766408]

36.Tamburin S, Faccini M, Casari R, Federico A, Morbioli L, Franchini E, Bongiovanni LG, Lugoboni F. Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. J Psychopharmacol. 2017 Oct;31(10):1369-1373. [PubMed: 28613124]

37.Tae CH, Kang KJ, Min BH, Ahn JH, Kim S, Lee JH, Rhee PL, Kim JJ. Paradoxical reaction to midazolam in patients undergoing endoscopy under sedation: Incidence, risk factors and the effect of flumazenil. Dig Liver Dis. 2014 Aug;46(8):710-5. [PubMed: 24893689]

38.Isbister GK, O’Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol. 2004 Jul;58(1):88-95. [PMC free article: PMC1884537] [PubMed: 15206998]

Disclosure: Nazila Sharbaf Shoar declares no relevant financial relationships with ineligible companies.

Disclosure: Karlyle Bistas declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.